FILE PHOTO: A health worker shows a vial of the AstraZeneca COVID-19 vaccine against the coronavirus disease (COVID-19) as Thailand start a mass inoculation at a gymnasium inside the Thammasat University in Pathum Thani, Thailand June 7, 2021. REUTERS/Athit Perawongmetha/File Photo
July 29, 2021
(Reuters) – AstraZeneca’s COVID-19 vaccine sales more than tripled to $894 million in the second quarter from the previous three months but shaved off 1 U.S. cent from earnings, and the drugmaker updated its 2021 forecasts on Thursday to include sales from its Alexion unit.
(Reporting by Pushkala Aripaka in Bengaluru and Alistair Smout in London)
Source: One America News Network
